Efficacy of dupilumab for the treatment of severe skin disease in cytotoxic T lymphocyte antigen-4 insufficiency: A role of type 2 inflammation?

We report on the successful treatment of a severe, recalcitrant dermatitis caused by CTLA-4 insufficiency with dupilumab, raising the possibility of a role of type 2 immunity in clinical conditions associated with CTLA-4 insufficiency.

Detalles Bibliográficos
Autores principales: Arruda, L. Karla, Cordeiro, Daniel L., Langer, Sarah S., Koenigham-Santos, Marcel, Calado, Rodrigo T., Dias, Marina M., Anhesini, Leonardo R., Oliveira, João Bosco, Grimbacher, Bodo, Ferriani, Mariana P.L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509893/
https://www.ncbi.nlm.nih.gov/pubmed/37780100
http://dx.doi.org/10.1016/j.jacig.2022.08.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509893/
https://www.ncbi.nlm.nih.gov/pubmed/37780100
http://dx.doi.org/10.1016/j.jacig.2022.08.004

Ejemplares similares